drugset / Trial / NCT02568332
A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals
Phase 1
Completed
20 enrolled
University of Oxford
Cantonal Hospital of St. Gallen · collabGlaxoSmithKline · collabReiThera Srl · collabSt. James's Hospital, Ireland · collab
NaSingle-groupOpen-labelPrevention
Summary
This study is aimed at assessing the safety of candidate Hepatitis C (Hep C) vaccines AdCh3NSmut1 and MVA-NSmut when administered to Human Immunodeficiency Virus (HIV) seropositive individuals. This study also aims to assess the cellular immune response generated by these vaccines when administered as mentioned above.
Timeline
- Start
- 2015-07-21
- Primary completion
- 2017-01-26
- Completion
- 2017-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AdCh3NSmut1 | Vaccine | 2.5e+10 unknown | — |
| Subject | MVA-NSmut | Vaccine | 2e+08 unknown | — |